{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:25:13Z","timestamp":1790871913663,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.thromres.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T11:38:54Z","timestamp":1524656334000},"page":"S77-S81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"S1","title":["Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-5299","authenticated-orcid":false,"given":"Marcel","family":"Levi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2018.01.016_bb0005","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0049-3848(14)50012-6","article-title":"Cancer-related coagulopathies","volume":"133","author":"Levi","year":"2014","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2008.12.005","article-title":"Disseminated intravascular coagulation in cancer patients","volume":"22","author":"Levi","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0015","first-page":"96","article-title":"Disseminated intravascular coagulation in patients with solid tumors","volume":"29","author":"Feinstein","year":"2015","journal-title":"Oncology (Williston Park, NY)"},{"issue":"1\u20132","key":"10.1016\/j.thromres.2018.01.016_bb0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000046589","article-title":"Thrombotic microangiopathy in the cancer patient","volume":"106","author":"Kwaan","year":"2001","journal-title":"Acta Haematol."},{"issue":"11","key":"10.1016\/j.thromres.2018.01.016_bb0025","first-page":"668","article-title":"Cancer and thrombosis","volume":"1","author":"Levi","year":"2003","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.thromres.2018.01.016_bb0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1055\/s-0037-1616139","article-title":"Disseminated intravascular coagulation in solid tumors: clinical and pathological study","volume":"86","author":"Sallah","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-2001-18865","article-title":"Disseminated intravascular coagulation in acute leukemia","volume":"27","author":"Barbui","year":"2001","journal-title":"Semin. Thromb. Hemost."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0040","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.V79.5.1305.1305","article-title":"High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia [see comments]","volume":"79","author":"Sarris","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2018.01.016_bb0050","first-page":"50","article-title":"Mechanisms of hypercoagulation in malignancy and during chemotherapy","volume":"28","author":"Falanga","year":"1998","journal-title":"Haemostasis"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0028-1087126","article-title":"Diffuse intravascular coagulation in liver disease?","volume":"4","author":"Straub","year":"1977","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-0030-1254045","article-title":"Disseminated intravascular coagulation: a disease-specific approach","volume":"36","author":"Levi","year":"2010","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2018.01.016_bb0065","series-title":"Blood: Principles and Practice of Hematology","article-title":"Disseminated intravascular coagulation","author":"Seligsohn","year":"2000"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197756010-00001","article-title":"Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features","volume":"56","author":"Sack","year":"1977","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.thromres.2018.01.016_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0002-8703(87)90719-8","article-title":"Nonbacterial thrombotic endocarditis: a review","volume":"113","author":"Lopez","year":"1987","journal-title":"Am. Heart J."},{"key":"10.1016\/j.thromres.2018.01.016_bb0080","article-title":"Phlegmasia alba dolens","volume":"695","author":"Trousseau","year":"1865","journal-title":"Clin. Med. Hotel Dieu Paris"},{"key":"10.1016\/j.thromres.2018.01.016_bb0085","first-page":"683","article-title":"Thrombophlebitis in cancer","volume":"134","author":"Illtyd","year":"1935","journal-title":"Practitioner"},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0090","doi-asserted-by":"crossref","first-page":"V187","DOI":"10.1016\/S0049-3848(01)00235-3","article-title":"Venous thromboembolism and occult malignancy","volume":"102","author":"Otten","year":"2001","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0095","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7326\/M17-0868","article-title":"Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data","volume":"167","author":"van Es","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0100","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0038-1657515","article-title":"Prevention of thrombotic disorders in cancer patients undergoing chemotherapy","volume":"78","author":"Levine","year":"1997","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.8-4-381","article-title":"Venous thrombosis in cancer patients: insights from the FRONTLINE survey","volume":"8","author":"Kakkar","year":"2003","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0120","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2018.01.016_bb0125","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cncr.10847","article-title":"A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma","volume":"95","author":"Desai","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.thromres.2018.01.016_bb0130","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"Kuenen","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0135","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2002.20.6.1657","article-title":"Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors","volume":"20","author":"Kuenen","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-994916","article-title":"Thrombotic complications of central venous catheters in cancer patients","volume":"25","author":"Bona","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"issue":"15","key":"10.1016\/j.thromres.2018.01.016_bb0145","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1200\/JCO.2002.11.135","article-title":"Complication rates among cancer patients with peripherally inserted central catheters","volume":"20","author":"Walshe","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.thromres.2018.01.016_bb0150","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1538-7836.2007.02660.x","article-title":"Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study","volume":"5","author":"Niers","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0155","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0160","first-page":"580","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"19","author":"Doll","year":"1992","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0165","first-page":"495","article-title":"Thrombotic microangiopathy following bone marrow transplantation","volume":"14","author":"Pettitt","year":"1994","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0170","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E","article-title":"Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome by protein A immunoadsorption of plasma","volume":"71","author":"Snyder","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V72.2.451.451","article-title":"Intravascular hemolysis and renal insufficiency after bone marrow transplantation","volume":"72","author":"Guinan","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2018.01.016_bb0180","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/ki.1989.132","article-title":"Delayed renal failure with extensive mesangiolysis following bone marrow transplantation","volume":"35","author":"Antignac","year":"1989","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.thromres.2018.01.016_bb0185","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.V77.8.1837.1837","article-title":"Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies","volume":"77","author":"Rabinowe","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1078155216628324","article-title":"Antineoplastic agents and thrombotic microangiopathy","volume":"23","author":"Garcia","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0200","first-page":"339","article-title":"Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?","volume":"3","author":"Chappell","year":"1988","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.thromres.2018.01.016_bb0205","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.V73.7.2018.2018","article-title":"Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation","volume":"73","author":"Holler","year":"1989","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1055\/s-0038-1642690","article-title":"Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice","volume":"74","author":"Donati","year":"1995","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nm0296-209","article-title":"In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease","volume":"2","author":"Contrino","year":"1996","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2008-1079253","article-title":"Tissue factor and cancer","volume":"34","author":"Rickles","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"issue":"18","key":"10.1016\/j.thromres.2018.01.016_bb0225","doi-asserted-by":"crossref","first-page":"8205","DOI":"10.1073\/pnas.92.18.8205","article-title":"Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation","volume":"92","author":"Bromberg","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.016_bb0230","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI117451","article-title":"Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice","volume":"94","author":"Zhang","year":"1994","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2008-1079259","article-title":"Heparanase, tissue factor, and cancer","volume":"34","author":"Nadir","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0240","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-2008-1079257","article-title":"Diverse roles of tissue factor-expressing cell subsets in tumor progression","volume":"34","author":"Milsom","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000331705","article-title":"Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature","volume":"81","author":"Hyman","year":"2011","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.thromres.2018.01.016_bb0250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-2007-994922","article-title":"The thrombophilic state in acute promyelocytic leukemia","volume":"25","author":"Tallman","year":"1999","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2018.01.016_bb0255","first-page":"S20","article-title":"The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia","volume":"8","author":"Rodeghiero","year":"1994","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.beha.2008.12.007","article-title":"The coagulopathy of acute promyelocytic leukaemia revisited","volume":"22","author":"Stein","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0265","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2014.11.026","article-title":"Thrombotic events in acute promyelocytic leukemia","volume":"135","author":"Mitrovic","year":"2015","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jth.12838","article-title":"Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH","volume":"13","author":"Thachil","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2018.01.016_bb0275","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(16)30101-3","article-title":"Management of cancer-associated disseminated intravascular coagulation","volume":"140","author":"Levi","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2018.01.016_bb0280","article-title":"Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia","volume":"6","author":"Marti-Carvajal","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.thromres.2018.01.016_bb0285","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jth.12838","article-title":"Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: reply","volume":"13","author":"Thachil","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.01.016_bb0290","first-page":"148a","article-title":"Low molecular weight heparin therapy and survival in advanced cancer","volume":"100","author":"Kakkar","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010569","article-title":"Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol","volume":"6","author":"Schunemann","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.thromres.2018.01.016_bb0300","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01097-2017","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials","volume":"50","author":"Di Minno","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.016_bb0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2006.07.007","article-title":"Mechanisms of heparin induced anti-cancer activity in experimental cancer models","volume":"61","author":"Niers","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"15","key":"10.1016\/j.thromres.2018.01.016_bb0310","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJM197010082831502","article-title":"Heparin therapy in septicemia with disseminated intravascular coagulation","volume":"283","author":"Corrigan","year":"1970","journal-title":"N. Engl. J. Med."},{"issue":"12 Suppl B","key":"10.1016\/j.thromres.2018.01.016_bb0315","first-page":"147","article-title":"Use of a low molecular weight heparin, CY 222, in the treatment of consumption coagulopathy","author":"Audibert","year":"1987","journal-title":"J. Mal. Vasc."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2007-1002795","article-title":"Treatment of disseminated intravascular coagulation","volume":"14","author":"Feinstein","year":"1988","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0325","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcrc.2005.09.005","article-title":"Prevalence, incidence, and risk factors for venous thromboembolism in intensive care unit patients","volume":"20","author":"Cook","year":"2005","journal-title":"J. Crit. Care"},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0330","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jcrc.2005.09.014","article-title":"Burden of illness in venous thromboembolism in critical care: a multicenter observational study","volume":"20","author":"Patel","year":"2005","journal-title":"J. Crit. Care"},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/cc4975","article-title":"Coagulation abnormalities in critically ill patients","volume":"10","author":"Levi","year":"2006","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.016_bb0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0345","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","article-title":"Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort","volume":"133","author":"Matsushita","year":"2014","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0350","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12185-017-2190-8","article-title":"Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku hematology forum","volume":"105","author":"Yokoyama","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.016_bb0355","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.thromres.2013.12.033","article-title":"Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - safety and efficacy in 1,032 patients with hematologic malignancy","volume":"133","author":"Asakura","year":"2014","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0360","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10147-014-0768-1","article-title":"Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial","volume":"20","author":"Tamura","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.thromres.2018.01.016_bb0365","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMra067742","article-title":"Prevention and treatment of major blood loss","volume":"356","author":"Mannucci","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8655","key":"10.1016\/j.thromres.2018.01.016_bb0370","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"2","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"issue":"26(6)","key":"10.1016\/j.thromres.2018.01.016_bb0375","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.2007.14.8486","article-title":"Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma","volume":"20","author":"Wheater","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.016_bb0380","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.bbmt.2007.01.070","article-title":"Recombinant factor VIIa to treat diffuse alveolar hemorrhage following allogeneic stem cell transplantation","volume":"13","author":"Shenoy","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.016_bb0385","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.mbc.0000224854.88366.05","article-title":"Recombinant activated factor VII for severe uterine bleeding after chemotherapy in a woman with acute myeloid leukemia","volume":"17","author":"Erikci","year":"2006","journal-title":"Blood Coagul. Fibrinolysis"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T08:00:02Z","timestamp":1604217602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818300161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":77,"alternative-id":["S0049384818300161"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.016","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}